🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cogstate Limited (ASX:CGS)
Australia flag Australia · Delayed Price · Currency is AUD
3.520
-0.030 (-0.85%)
Nov 23, 2026, 10:14 AM AEDT
← View all transcripts

Bell Potter Healthcare Conference

Nov 18, 2026

Summary

FY26 sales contracts reached $89m, with September-quarter sales up 17% YoY and $143.7m of contracted revenue. Growth plans center on expanding trials and indications, Medidata’s channel reach, and AI-enabled operating leverage.

Hello, and welcome back to the Bell Potter Healthcare Conference. For our next presentation, we are really pleased to welcome Brad O'Connor, the CEO of Cogstate, into the studio. Brad, thanks for coming in today. Thank you. Thanks for having me. I am going to do a quick introduction, and then we will go through some slides. For the audience out there, Cogstate provides technology and services for companies conducting clinical trials, predominantly in central nervous system disorders, or CNS disorders. This is a world where a successful primary endpoint readout is make or break for a drug developer, so ensuring the highest chance of success is absolutely crucial, and that is where Cogstate comes in. The company has a proven track record working with over 160 different customers to date, and well over 100 different clinical trials at any one time, so are deeply involved in the sector. The last year and a half has seen a considerable uptick in Cogstate's contract wins and share price, as the company has successfully diversified into new therapeutic areas and service offerings. With that intro, Brad, thanks again for joining us. We will go through a few slides and ask some questions throughout, and maybe afterwards. Perfect. Thank you, Thomas. And hello, everybody. As Thomas said, my name's Brad O'Connor. I'm the Chief Executive, and I've been a role I've been pleased to be in since 2005, so some time. As Thomas mentioned, Cogstate, we're a global company helping pharma and biopharma companies develop their drugs. We're the picks and shovels to drug development, if you like, but with a prioritization around brain health or central nervous system disease trials. Just a little bit of scene setting for people who may not be familiar with Cogstate. Our ticker is CGS, around a $600 million Aussie market cap. Some of the largest shareholders there are noted. The Myer family noted as our second-largest shareholder there. Martyn Myer is our Chairman and put the original seed capital into the business back in 1999. The Dolby family noted there, people will be familiar with Dolby Labs, Dolby Surround Sound. So that's the Dolby family out of San Francisco. We're around 180 full-time employees across the business, mainly in the U.S., so it's very much a U.S. business, and our customers are very much U.S. pharma companies. We're around 30 people in Australia and 12 people in the U.K. But we enhance that full-time employee base with over 450 now consulting neuropsychologists who help provide our services in over 50 languages. Our customer base, as I mentioned, is pharma and biotech. And then just in terms of from an investment point of view, in the context of what's happening more globally in the economy, because it's healthcare R&D, it tends to be countercyclical to what's happening in terms of interest rates and retail spending and things like that. Not influenced by those kind of things. The really high-level investment case before we get into it. Cogstate is a profitable and growing business. In FY 2026, we delivered a little over $60 million U.S. of revenue at 25% EBIT margins, and we have strong visibility to revenue growth at 20% plus over the coming years. Well-capitalized balance sheet, $35 million net cash, U.S. dollars again. I should have stated at the start, all of the figures I'll point to today are in U.S. dollars, just to confuse everybody in Australian dollars. But over $35 million U.S. net cash, no debt, strong cash generation, which allows for self-funded growth. We're at a sales inflection point. We'll talk as we get through the presentation today as to why that's happening, but sales in central nervous system diseases are growing, which is helping grow our revenue. We have technology-driven operating leverage. Again, I'll talk to that as we go through the presentation. But like most businesses, we're looking at technology and AI to improve the operating leverage in our business over the next couple of years. And we think we have a unique competitive position in what's a relatively small competitive space. We really have two competitors, so it's a small oligopoly sort of servicing this market. How do we earn revenue? What does Cogstate actually do? What we do is help remove error from clinical trials. When you are working in central nervous system disease clinical trials, the assessment is generally speaking a neuropsychologist or a doctor of some kind delivering to the patient a questionnaire and interpreting the results from that patient. The problem with that comes that there is a degree of subjectivity when those doctors deliver those assessments. That works fine when an individual patient is seeing their individual doctor. Where that becomes difficult is when we industrialize clinical trials and drug development. Once we change that dynamic and we move out to, say, 20 countries in 30 languages with 600 or 700 doctors all delivering those assessments, what you get is minor variations in that delivery of that assessment, and that can bring error or noise into the data. At the end of the day, what we sell to our customer is signal over noise. By taking error out of your data, we will increase your signal strength and therefore give you a more accurate representation of whether that drug is working or not. There is a range of ways we do that. In terms of how we go to market or how do we sell, that is an area that has changed for us substantially over the last couple of years. Cogstate will sell directly to a pharma company. We will also often sell to the contract research organization or the firm that is charged with running a clinical trial. Oftentimes, we will now do that via what we call a channel partner. The companies that are listed on screen there, all provide electronic data capture technologies into clinical trials. The largest that is noted there is a company called Medidata. Medidata is a large company doing about $1.2 billion US of revenue annually. They were acquired by a French company called Dassault Systèmes in 2019 for $5.8 billion. So a really large organization. What we have done is to partner with Medidata as they push, I should say, into central nervous system disease trials. What we do is enable their commercial team to sell their technology into central nervous system disease trials. Without the services wraparound and technology wraparound that Cogstate provides, Medidata cannot sell into that market. That has been really important for us as we have grown over the last couple of years. They have certainly increased our shots on goal. They have a commercial team of around 700 people, which compares to our commercial team of six people. You get a sense for the size and scale, and obviously really well established in terms of customer relationships. We have been able to leverage off those customer relationships as we have grown our contracts. I might jump in, Brad, and just dive a bit deeper into Medidata. Can you run us through, I guess, from a customer perspective, how this collaboration with Medidata works? I can imagine a pharma company goes to one of these companies for a data capture system. If they go to Medidata, is Medidata saying, "Hey, you should really think about incorporating Cogstate for your endpoint management?" How is that playing out? Yeah. Medidata largely will be They're a SaaS company, a SaaS technology company, and so they'll have a number of their customers as subscription customers, right? The pharma company will be using the Medidata technology anyway in all of their other clinical trials, so they'll have established protocols. Yeah. They'll have the ability to pipe that data from the Medidata system directly into their analytics and things like that. That'll all be established. What the advantage is for us in Medidata, when we go to these new customers, right, they'll be already a Medidata customer. Right. They will have that established protocols, the established familiarity with the Medidata system. What we enable them to do is to say, "In the same way as you use Medidata in your oncology studies or your diabetes studies or whatever it is, you can now use that same Medidata system in your central nervous system disease trials. Okay. Right? It is an easier sell from that point of view. Got you. In our last quarterly, we will get to that as we go through the presentation, but we noted in that quarterly that we had a number of competitive phase III wins. So where companies were taking new drugs into phase III clinical trials, and we were able to competitively win those away from the incumbents. Right. A major factor in that win was the fact that those customers were already existing Medidata customers. Okay. There was both a pricing advantage because they already had a subscription to the Medidata technology. Right. Right? There is a pricing advantage, and then there was the familiarity and the process advantage. Okay in going with Medidata. Let me just kind of say that back and make sure I am on the same page here. A lot of these customers already have Medidata, but typically in oncology and non-CNS trials. Correct. I guess the question then is, why does Medidata, in kind of partnership with you, allow Medidata to get into CNS? Why couldn't they have been doing this already? Yeah. The difference comes with the types of assessment that you are using in a central nervous system disease trial. If you are in an oncology trial, you will be measuring something like tumor shrinkage. Survival. Survival rate. There is a right and wrong answer. Black and white. There is black and white. Exactly. The degree of subjectivity that we talked about before that comes into these assessments used in CNS trials means you have to overlay a services aspect to that to make sure that the doctors who are administering it are all trained to deliver it in the same way, that we are reviewing that data, looking for whether the doctor made any mistakes, and correcting that error. Yeah. Medidata does not offer those services. You do not need any of that really in an oncology trial. No, correct. Yeah, got you. Correct. Okay. Correct. All right. Medidata seems to really be hitting its strides. Let's keep pressing on. Okay. Excellent. Just a really quick highlight of the FY 2026 results. I know these are getting a little stale now that we are pushing towards the end of the 2026 calendar year. But really strong sales performance for FY 2026, $89 million worth of sales contracts. I should just point out there how we sell. When we sign a contract for each individual clinical trial, that includes a detailed breakdown of all the services and technology we will provide into that trial. It comes to a total contract value. That revenue then rolls off over the length of that clinical trial. There are two really important financial numbers when you are looking at Cogstate. One is the amount of sales contracts, and that really points to future revenue, and then revenue that is recognized, which is the runoff of those sales contracts. Anyway, $89 million of sales contracts executed FY 2026. Running a much larger book of clinical trials, up to 171 clinical trials now. And contracted revenue base, you can see there, really strong contracted revenue base that will roll off over future periods. Just under $61 million of revenue, as I mentioned before. Just a little shy of 60% gross margins in the business. And a $16 million U.S. profit before tax. $35 million net cash. We have been continuing to invest in the business, and from a capital allocation point of view, we have been both buying back our shares, so we have bought back about 7% of the stock that is on the market over the last couple years, and we also pay a dividend. We paid our second annual dividend in September this year of four Australian cents per share. That momentum has then continued. If we look to the September quarter results, just a little over $25 million worth of sales contracts executed in that September quarter, which is up 17% on the previous corresponding period. I mentioned before that we had those competitive wins that helped contribute to that $25 million. So really strong quarter for us as we continue that momentum that we saw in FY 2026 and look forward to continuing that for the remainder of FY 2027. I might just- Sure get you to go back, and let's dive into a bit of that. In the quarter, you specifically called out there were a few phase III trials that you guys were able to win successfully. Normally, if a company uses certain vendors for phase II, that's a positive trial, then they'll want to keep it consistent for phase III. But it sounds like there's a few switches. Why do those customers in those instances switch to Cogstate's endpoint management Yeah when they were clearly using someone else in the phase II? Yeah. I think the first thing to just to dig into there, you're 100% right that we sort of think of it as we sort of attach ourselves to a compound. Yep. Generally speaking, we win work in phase II. Yep. Then if that is successful, we follow it through to phase III. So to win work like this in phase III when we were not involved in the phase II is actually really hard. Really, as I pointed out before, that is really the strength of that Medidata relationship, right? Both of those customers, so there are two customers here across those phase IIIs. One of them, a really large phase III, then another one where they are taking the same compound into different disorders. So there is one, a bipolar- Got you. an anxiety, and a depression phase III in all of those with the same compound. It was really those existing relationships with Medidata that helped us win that. So that has been really important to us. Yeah, great. Just on that slide, we can see how the quarterly evolution of your contract sales has progressed. The last five or six quarters have been really nice and pretty consistent. But there is a degree of volatility quarter to quarter, right? Because you are dependent on your customers and when they sign a contract on their trial. So maybe just take a second to talk through how each quarter to quarter looks, because it has been a good run. What more can you say? Yeah. I think, I get a lot of comments around everyone's very happy to see that consistency of sales. I always say to people, "Don't get too comfortable with that." We could easily see a $40 million quarter, and we could see a $5 million quarter. Because it is just a 12-week period, and as you suggest, we do not control when the customer signs that contract and when they are ready to go. Yeah. Yeah. What I would say is that we have a large, we have got the largest sort of book of work we are bidding on ever at the moment. So we have got good visibility into an increase in the amount of work. That is your pipeline, effectively. Pipeline of work. But the challenge is always, when do we get that executed? Yeah. Right? I mean, I think it feels like every quarter that I am harassing our sales team as to why we do not sign anything in the first six weeks, and we sign everything in the last six weeks of the quarter. Yeah. Right. We are up to that time of the year again as we push towards 31 December. Look, again, we are looking at a good amount of work this quarter. It can be, from a running the business point of view, if we sign something in the second last week of December or the second week of January. Yeah It makes no difference to the running of the business. It makes no difference to our revenue. Yeah. Right? It is just that point in time. Yeah. You do see that variability of that. I think the other thing we would point out with that graph is when you go back to that first quarter of FY 2025, you can obviously see a downward trend there that we were running through at that time, which has now picked up, which reflects, I think, what is happening in the market more broadly. Right? More central nervous system disease trials. It reflects the fact that we have expanded the indications in which we work in. Yeah. We are working in more disease areas. It reflects our go-to-market strategy and the impact Medidata has had on that. All of those things are contributing to that increase in sales. Yeah. Great. As we push through, what that increase in sales means is we have this contracted revenue. That is $143.7 million called out there. That is revenue under contract that will run off over the next few years. The graph on the left really shows you the breakdown of how that is going to run off. So how much in FY 2027, FY 2028, FY 2029, et cetera. At the end of the September quarter, just a little shy of $57 million already locked in for FY 2027. Obviously, that will increase as we sign contracts in the December, March, and June quarters, how much revenue we are going to recognize in each of those periods. That puts us in a really good spot compared to where we have been in previous years. Really, the table on the bottom right there really just shows you what that looks like from period to period, how that has grown from 30 June 2026 to that September quarter, in terms of by signing those $25 million worth of contracts, how we have been able to add revenue into this year and then subsequent years. Yeah. I will jump in with a question. It is somewhat related to your pipeline and contracted outlook. We hear a lot about Alzheimer's disease. It is obviously where you have historically been really strong, and there are some really interesting readouts coming up from Lilly and others about doing their trials in pre-symptomatic patients. Let's assume that, as many in the industry expect, that these drugs that are out there are more effective in pre-symptomatic patients. What does that mean for Cogstate's ability to service that market and potential implications for pipeline opportunities? Yeah, so I think that's right. For those who aren't familiar with the Alzheimer's disease space, there's two drugs on market presently, approved for the treatment of early Alzheimer's disease. Both of those drugs now are pushing into a pre-symptomatic population. What that means is people have these protein buildups in their brain that are associated with Alzheimer's disease, but they're not yet suffering from cognitive impairment and memory loss. The hope is, what we can do is treat people before they get sick, Yeah rather than just managing their decline. I think for Cogstate, what that means is just, if we can see, and I think we'll probably have data, probably around 12 months from now, in those trials. If those play out, I think that means that the addressable market, or the pharma company selling these drugs to gets much larger. Which means much larger revenue opportunity for the pharma company, which means a substantial increase in R&D spend as they seek to attack that market. Yeah. Okay. Are you seeing, in general terms, the RFPs for Alzheimer's has kind of petered down, stayed the same, or increased in recent years? So, it's actually slowed down a little bit, over the last 12 months, in terms of what we're seeing in Alzheimer's disease. We think that will pick back up again over the next 12 months. Yeah. A lot of that is sort of waiting for this next layer of data to come through. Yeah, interesting. Great. So, just pushing along. The drivers of growth, as we were sort of just talking about there, is the increased investment in central nervous system disease trials. We are seeing that across the board. As the population is aging, the health span or how many good years you have left becomes important as opposed to just lifespan. We are seeing that investment in central nervous system diseases and a real focus on brain health. Cogstate is also expanding the indications, so those disease areas that we work in. Particularly important there is that expansion to psychiatry and mood, which has been really important to us. We are also expanding our service offerings. The number of services that we are offering in each of those indications is also expanding. Our go-to-market strategy we have talked about extensively today, with the Medidata partnership is changing, right? Then we are seeing also a maturation of the current portfolio. I think the thing that is really important there to point out is the number of phase II trials that we are running. We talked before about how we want to win that work at phase II and then follow it through to phase III, right? We have 45 phase II trials at 30 June 2025, and then up to 78 at 30 June 2026. So, real expansion in that phase II work, which means that the ability to win into phase III just increases there. Yeah. Okay, to say that back in another way, tell me if this is reasonable. Phase IIs are a leading indicator to a phase III. Obviously, not all phase IIs get up and get funded, but they are a leading indicator, and it is the phase III trials which are naturally the largest and most lucrative contract values. Correct. Correct. We just sort of, as you increase that pool of phase IIs. Yeah as you say, not all of them go through to a phase III, but a bunch will. Is that the most phase IIs you guys have ever been working on? Yeah, 100%. Yeah. 171 clinical trials in total at 30 June 2026. We will push well in excess of 200 clinical trials by the time we get to the end of FY 2027. So, that book of work is just growing. Right. That leads me into a question, and maybe you will get to it, but it is around leverage and the ability to scale. Clearly, you have got an increasing demand- Yeah in the number of trials you're having to run. What's the ability of Cogstate to work on 300, 400, 500 trials at any one time, as the years get along? Yeah. I think the important thing to call out there is the work we're doing, and I might just skip forward to this next slide, is the work we're doing around the reconfiguration of our operating model. AI for us has two focus areas. The first is in terms of new product. Yeah. Right? We've got these proprietary data sets on which we're training specific models to deliver more value to our customers in terms of an AI-enabled product. Then the other aspect that we're doing, and what many businesses are doing, is rethinking how do we actually run our business? What happens behind the scenes? Yeah. Okay. We're doing an extensive exercise at the moment to deliver a much more technology-driven operating model for our staff. Right. Right? We think that will provide substantial leverage over our staff into the future. There's a couple of things there that we think that we've gone through an extensive review process and design process, and we think there's over a 50% reduction in manual work that we can achieve through this. Then, in theory, that should increase gross margins. I think the only caveat we put to that is, and this is what every company's finding with, as they deliver technology efficiency- The question then becomes, can you maintain pricing or how much of that technology dividend do you need to give back to your customers? I think that's the only aspect that's unknown at this stage. Great. Any other slides that you wanted to get through or is that pretty much? I think they are the main things. I think, look, just to summarize, I think the business is in really good shape. We are continuing to expand our customer base, expand the disease areas that we are working into, and then now investing in technology to deliver increased returns from that business. Yeah, great. We got about a minute or two to go, so let me just touch on capital deployment. So you announced a dividend, I think it is in second year now. You have got plenty of cash, profitable. How is the board and the company balancing these internal investments Yeah to become more scalable versus returns or M&A or whatever it may be? Yeah. So we've been running the share buyback for a couple of years, and as we mentioned, bought back about 7% of the stock. I think that's produced a good return for average buyback price of $1.31. Compared to the current price, that's been a good decision. We're committed to that 20%-50% of NPAT as a dividend as we go forward, fully franked. Then, continuing to invest in technology. We're looking at a couple of small things that we might consider acquiring, but we're a little wary of acquisitions in the current environment. The concern being that you end up paying for goodwill in a business that gets replaced by AI. Right? Because we've got such a visibility to growth as it is, we don't want to take risks around that. We'd rather develop the technology and continue to develop the product internally. Yeah, great. All right. Look, we've got a question or two on the line, so we'll just get to one of these. We've got a question saying, "five years from now, what percentage of your revenue do you think could come from outside Alzheimer's as opposed to within Alzheimer's disease? Yeah. Alzheimer's disease today probably still represents something like 50% of our revenue base. Yeah Today. But if you have a look at our sales contracts over the last 12 months, real increase in mood disorders particularly. Certainly in the September quarter, it was mainly in the mood disorder space. I think, as we push forward, I think we will see the continued diversification of that revenue base away from Alzheimer's disease, and potentially even away from central nervous system diseases. Okay As we continue to add product and change our focus areas to match what our customers are looking for. Right. Yeah, someone mentioned dermatology. Is that something that could ever be used? No, 100%. We've just kicked off our first dermatology There you go. study. It makes no sense what business do we have in dermatology, but the infrastructure exists in terms of all the things that we have in place. We deliver telehealth-style assessments in central nervous system disease now. Oh, yeah. Okay. A bunch of those trials, the assessments are done by telehealth. Absolutely. Yeah. We're just switching out a neuropsychologist for a dermatologist. Yeah. Okay. and essentially, the piping is the same, if you like. Yeah, so as, I guess, telehealth and remote trials become more mainstream, you're somewhat leveraged to that. Yeah, 100%. Yeah. Okay. Hey, we are done for time, unfortunately. Could keep going, but we'll have to wrap it up there. Thank you so much. Thanks, Brad. It has been great to run through and, yeah, we will keep looking to these next quarterly updates. Thanks, Thomas. All right. Thanks, everyone. We are going to go to a quick break. We are going to be back with our next presentation. We have Orthocell, so we will be back in a minute.